APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Analysis and Forecast 2026-2032

23 December 2025203 pages

Choose your research edition.

Industry ResearchDrugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae include Takeda Pharmaceutical, CSPC, Shenzhen Lijian Pharmaceutical, Sanofi, Merck & Co., Inc. (USA), Roche, Pfizer Inc. (USA), NCPC and Sinopharm Group, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae, also provides the revenue of main regions and countries. Of the upcoming market potential for Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae revenue, projected growth trends, production technology, application and end-user industry.

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Segment by Company

Takeda Pharmaceutical

CSPC

Shenzhen Lijian Pharmaceutical

Sanofi

Merck & Co., Inc. (USA)

Roche

Pfizer Inc. (USA)

NCPC

Sinopharm Group

GlaxoSmithKline plc (UK)

Daiichi Sankyo

Bayer

AbbVie

Sun Pharmaceutical

Lupin

Hikma Pharmaceuticals

Dr. Reddy's Laboratories

Cipla

Celltrion

Astellas Pharma Inc. (Japan)

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Segment by Type

Ceftriaxone

Doxycycline

Other

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Segment by Application

Retail Pharmacy

Hospital

Other

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ceftriaxone Major Player Table 3. Doxycycline Major Player Table 4. Other Major Player Table 5. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Retail Pharmacy Major Player Table 7. Hospital Major Player Table 8. Other Major Player Table 9. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Trends Table 10. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Drivers Table 11. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Opportunities and Challenges Table 12. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Restraints Table 13. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Region (2021-2026) Table 16. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Region (2027-2032) Table 18. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Players (2021-2026) Table 20. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Key Players Headquarters & Area Served Table 22. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players, Product Type & Application Table 23. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Type (2021-2026) Table 30. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Type (2027-2032) Table 31. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Application (2021-2026) Table 35. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Application (2027-2032) Table 36. Takeda Pharmaceutical Company Information Table 37. Takeda Pharmaceutical Business Overview Table 38. Takeda Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Takeda Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 40. Takeda Pharmaceutical Recent Development Table 41. CSPC Company Information Table 42. CSPC Business Overview Table 43. CSPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. CSPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 45. CSPC Recent Development Table 46. Shenzhen Lijian Pharmaceutical Company Information Table 47. Shenzhen Lijian Pharmaceutical Business Overview Table 48. Shenzhen Lijian Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Shenzhen Lijian Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 50. Shenzhen Lijian Pharmaceutical Recent Development Table 51. Sanofi Company Information Table 52. Sanofi Business Overview Table 53. Sanofi Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Sanofi Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 55. Sanofi Recent Development Table 56. Merck & Co., Inc. (USA) Company Information Table 57. Merck & Co., Inc. (USA) Business Overview Table 58. Merck & Co., Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Merck & Co., Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 60. Merck & Co., Inc. (USA) Recent Development Table 61. Roche Company Information Table 62. Roche Business Overview Table 63. Roche Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Roche Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 65. Roche Recent Development Table 66. Pfizer Inc. (USA) Company Information Table 67. Pfizer Inc. (USA) Business Overview Table 68. Pfizer Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Pfizer Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 70. Pfizer Inc. (USA) Recent Development Table 71. NCPC Company Information Table 72. NCPC Business Overview Table 73. NCPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. NCPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 75. NCPC Recent Development Table 76. Sinopharm Group Company Information Table 77. Sinopharm Group Business Overview Table 78. Sinopharm Group Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Sinopharm Group Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 80. Sinopharm Group Recent Development Table 81. GlaxoSmithKline plc (UK) Company Information Table 82. GlaxoSmithKline plc (UK) Business Overview Table 83. GlaxoSmithKline plc (UK) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. GlaxoSmithKline plc (UK) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 85. GlaxoSmithKline plc (UK) Recent Development Table 86. Daiichi Sankyo Company Information Table 87. Daiichi Sankyo Business Overview Table 88. Daiichi Sankyo Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Daiichi Sankyo Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 90. Daiichi Sankyo Recent Development Table 91. Bayer Company Information Table 92. Bayer Business Overview Table 93. Bayer Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Bayer Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 95. Bayer Recent Development Table 96. AbbVie Company Information Table 97. AbbVie Business Overview Table 98. AbbVie Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. AbbVie Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 100. AbbVie Recent Development Table 101. Sun Pharmaceutical Company Information Table 102. Sun Pharmaceutical Business Overview Table 103. Sun Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Sun Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 105. Sun Pharmaceutical Recent Development Table 106. Lupin Company Information Table 107. Lupin Business Overview Table 108. Lupin Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Lupin Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 110. Lupin Recent Development Table 111. Hikma Pharmaceuticals Company Information Table 112. Hikma Pharmaceuticals Business Overview Table 113. Hikma Pharmaceuticals Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Hikma Pharmaceuticals Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 115. Hikma Pharmaceuticals Recent Development Table 116. Dr. Reddy's Laboratories Company Information Table 117. Dr. Reddy's Laboratories Business Overview Table 118. Dr. Reddy's Laboratories Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Dr. Reddy's Laboratories Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 120. Dr. Reddy's Laboratories Recent Development Table 121. Cipla Company Information Table 122. Cipla Business Overview Table 123. Cipla Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Cipla Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 125. Cipla Recent Development Table 126. Celltrion Company Information Table 127. Celltrion Business Overview Table 128. Celltrion Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Celltrion Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 130. Celltrion Recent Development Table 131. Astellas Pharma Inc. (Japan) Company Information Table 132. Astellas Pharma Inc. (Japan) Business Overview Table 133. Astellas Pharma Inc. (Japan) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Astellas Pharma Inc. (Japan) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 135. Astellas Pharma Inc. (Japan) Recent Development Table 136. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2026) & (US$ Million) Table 137. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2027-2032) & (US$ Million) Table 138. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2026) & (US$ Million) Table 139. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2027-2032) & (US$ Million) Table 140. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021-2026) & (US$ Million) Table 142. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (US$ Million) & (2027-2032) Table 143. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2026) & (US$ Million) Table 144. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2027-2032) & (US$ Million) Table 145. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2026) & (US$ Million) Table 146. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2027-2032) & (US$ Million) Table 147. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 148. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021-2026) & (US$ Million) Table 149. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (US$ Million) & (2027-2032) Table 150. China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2026) & (US$ Million) Table 151. China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2027-2032) & (US$ Million) Table 152. China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2026) & (US$ Million) Table 153. China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2027-2032) & (US$ Million) Table 154. Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2026) & (US$ Million) Table 155. Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2027-2032) & (US$ Million) Table 156. Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2026) & (US$ Million) Table 157. Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2027-2032) & (US$ Million) Table 158. Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Region (US$ Million) & (2021-2026) Table 160. Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Region (US$ Million) & (2027-2032) Table 161. SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2026) & (US$ Million) Table 162. SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2027-2032) & (US$ Million) Table 163. SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2026) & (US$ Million) Table 164. SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2027-2032) & (US$ Million) Table 165. SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 166. SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021-2026) & (US$ Million) Table 167. SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (US$ Million) & (2027-2032) Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Image Figure 2. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ceftriaxone Image Figure 5. Doxycycline Image Figure 6. Other Image Figure 7. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size Share 2021 VS 2025 VS 2032 Figure 9. Retail Pharmacy Image Figure 10. Hospital Image Figure 11. Other Image Figure 12. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size (US$ Million) & (2021-2032) Figure 13. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Type (2021-2032) Figure 20. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Application (2021-2032) Figure 23. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Type (2021-2032) Figure 25. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Application (2021-2032) Figure 26. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Country (2021-2032) Figure 27. United States Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Type (2021-2032) Figure 32. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Application (2021-2032) Figure 33. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Country (2021-2032) Figure 34. Germany Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Type (2021-2032) Figure 44. China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Application (2021-2032) Figure 45. Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Type (2021-2032) Figure 47. Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Application (2021-2032) Figure 48. Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Region (2021-2032) Figure 49. Japan Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Type (2021-2032) Figure 57. SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Application (2021-2032) Figure 58. SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Country (2021-2032) Figure 59. Brazil Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Ceftriaxone
  • Doxycycline
  • Other
Applications
  • Retail Pharmacy
  • Hospital
  • Other
Companies covered
  • Takeda Pharmaceutical
  • CSPC
  • Shenzhen Lijian Pharmaceutical
  • Sanofi
  • Merck & Co., Inc. (USA)
  • Roche
  • Pfizer Inc. (USA)
  • NCPC
  • Sinopharm Group
  • GlaxoSmithKline plc (UK)
  • Daiichi Sankyo
  • Bayer
  • AbbVie
  • Sun Pharmaceutical
  • Lupin
  • Hikma Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Cipla
  • Celltrion
  • Astellas Pharma Inc. (Japan)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market by Type
  3. 1.2.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ceftriaxone
  5. 1.2.3 Doxycycline
  6. 1.2.4 Other
  7. 1.3 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market by Application
  8. 1.3.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Retail Pharmacy
  10. 1.3.3 Hospital
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Dynamics
  1. 2.1 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Trends
  2. 2.2 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Drivers
  3. 2.3 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Opportunities and Challenges
  4. 2.4 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Perspective (2021-2032)
  2. 3.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Growth Trends by Region
  3. 3.2.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Region (2021-2026)
  5. 3.2.3 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Players
  2. 4.1.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Players (2021-2026)
  3. 4.1.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Key Players Headquarters & Area Served
  7. 4.4 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players, Product Type & Application
  8. 4.5 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market CR5 and HHI
  11. 4.6.3 2025 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Tier 1, Tier 2, and Tier 3
5 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Type
  1. 5.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2032)
  3. 5.3 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Type (2021-2032)
6 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Application
  1. 6.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2032)
  3. 6.3 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical
  2. 7.1.1 Takeda Pharmaceutical Company Information
  3. 7.1.2 Takeda Pharmaceutical Business Overview
  4. 7.1.3 Takeda Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Recent Developments
  7. 7.2 CSPC
  8. 7.2.1 CSPC Company Information
  9. 7.2.2 CSPC Business Overview
  10. 7.2.3 CSPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  11. 7.2.4 CSPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  12. 7.2.5 CSPC Recent Developments
  13. 7.3 Shenzhen Lijian Pharmaceutical
  14. 7.3.1 Shenzhen Lijian Pharmaceutical Company Information
  15. 7.3.2 Shenzhen Lijian Pharmaceutical Business Overview
  16. 7.3.3 Shenzhen Lijian Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Shenzhen Lijian Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  18. 7.3.5 Shenzhen Lijian Pharmaceutical Recent Developments
  19. 7.4 Sanofi
  20. 7.4.1 Sanofi Company Information
  21. 7.4.2 Sanofi Business Overview
  22. 7.4.3 Sanofi Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sanofi Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  24. 7.4.5 Sanofi Recent Developments
  25. 7.5 Merck & Co., Inc. (USA)
  26. 7.5.1 Merck & Co., Inc. (USA) Company Information
  27. 7.5.2 Merck & Co., Inc. (USA) Business Overview
  28. 7.5.3 Merck & Co., Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Merck & Co., Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  30. 7.5.5 Merck & Co., Inc. (USA) Recent Developments
  31. 7.6 Roche
  32. 7.6.1 Roche Company Information
  33. 7.6.2 Roche Business Overview
  34. 7.6.3 Roche Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Roche Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  36. 7.6.5 Roche Recent Developments
  37. 7.7 Pfizer Inc. (USA)
  38. 7.7.1 Pfizer Inc. (USA) Company Information
  39. 7.7.2 Pfizer Inc. (USA) Business Overview
  40. 7.7.3 Pfizer Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  42. 7.7.5 Pfizer Inc. (USA) Recent Developments
  43. 7.8 NCPC
  44. 7.8.1 NCPC Company Information
  45. 7.8.2 NCPC Business Overview
  46. 7.8.3 NCPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  47. 7.8.4 NCPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  48. 7.8.5 NCPC Recent Developments
  49. 7.9 Sinopharm Group
  50. 7.9.1 Sinopharm Group Company Information
  51. 7.9.2 Sinopharm Group Business Overview
  52. 7.9.3 Sinopharm Group Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sinopharm Group Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  54. 7.9.5 Sinopharm Group Recent Developments
  55. 7.10 GlaxoSmithKline plc (UK)
  56. 7.10.1 GlaxoSmithKline plc (UK) Company Information
  57. 7.10.2 GlaxoSmithKline plc (UK) Business Overview
  58. 7.10.3 GlaxoSmithKline plc (UK) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  59. 7.10.4 GlaxoSmithKline plc (UK) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  60. 7.10.5 GlaxoSmithKline plc (UK) Recent Developments
  61. 7.11 Daiichi Sankyo
  62. 7.11.1 Daiichi Sankyo Company Information
  63. 7.11.2 Daiichi Sankyo Business Overview
  64. 7.11.3 Daiichi Sankyo Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Daiichi Sankyo Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  66. 7.11.5 Daiichi Sankyo Recent Developments
  67. 7.12 Bayer
  68. 7.12.1 Bayer Company Information
  69. 7.12.2 Bayer Business Overview
  70. 7.12.3 Bayer Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bayer Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  72. 7.12.5 Bayer Recent Developments
  73. 7.13 AbbVie
  74. 7.13.1 AbbVie Company Information
  75. 7.13.2 AbbVie Business Overview
  76. 7.13.3 AbbVie Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  77. 7.13.4 AbbVie Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  78. 7.13.5 AbbVie Recent Developments
  79. 7.14 Sun Pharmaceutical
  80. 7.14.1 Sun Pharmaceutical Company Information
  81. 7.14.2 Sun Pharmaceutical Business Overview
  82. 7.14.3 Sun Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Sun Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  84. 7.14.5 Sun Pharmaceutical Recent Developments
  85. 7.15 Lupin
  86. 7.15.1 Lupin Company Information
  87. 7.15.2 Lupin Business Overview
  88. 7.15.3 Lupin Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Lupin Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  90. 7.15.5 Lupin Recent Developments
  91. 7.16 Hikma Pharmaceuticals
  92. 7.16.1 Hikma Pharmaceuticals Company Information
  93. 7.16.2 Hikma Pharmaceuticals Business Overview
  94. 7.16.3 Hikma Pharmaceuticals Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Hikma Pharmaceuticals Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  96. 7.16.5 Hikma Pharmaceuticals Recent Developments
  97. 7.17 Dr. Reddy's Laboratories
  98. 7.17.1 Dr. Reddy's Laboratories Company Information
  99. 7.17.2 Dr. Reddy's Laboratories Business Overview
  100. 7.17.3 Dr. Reddy's Laboratories Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Dr. Reddy's Laboratories Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  102. 7.17.5 Dr. Reddy's Laboratories Recent Developments
  103. 7.18 Cipla
  104. 7.18.1 Cipla Company Information
  105. 7.18.2 Cipla Business Overview
  106. 7.18.3 Cipla Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Cipla Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  108. 7.18.5 Cipla Recent Developments
  109. 7.19 Celltrion
  110. 7.19.1 Celltrion Company Information
  111. 7.19.2 Celltrion Business Overview
  112. 7.19.3 Celltrion Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Celltrion Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  114. 7.19.5 Celltrion Recent Developments
  115. 7.20 Astellas Pharma Inc. (Japan)
  116. 7.20.1 Astellas Pharma Inc. (Japan) Company Information
  117. 7.20.2 Astellas Pharma Inc. (Japan) Business Overview
  118. 7.20.3 Astellas Pharma Inc. (Japan) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Astellas Pharma Inc. (Japan) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  120. 7.20.5 Astellas Pharma Inc. (Japan) Recent Developments
8 North America
  1. 8.1 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (2021-2032)
  2. 8.2 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2032)
  3. 8.2.1 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2026)
  4. 8.2.2 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2027-2032)
  5. 8.3 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Type (2021-2032)
  6. 8.4 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2032)
  7. 8.4.1 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2026)
  8. 8.4.2 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2027-2032)
  9. 8.5 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Application (2021-2032)
  10. 8.6 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country
  11. 8.6.1 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021-2026)
  13. 8.6.3 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (2021-2032)
  2. 9.2 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2027-2032)
  5. 9.3 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2027-2032)
  9. 9.5 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country
  11. 9.6.1 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (2021-2032)
  2. 10.2 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2032)
  3. 10.2.1 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2026)
  4. 10.2.2 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2027-2032)
  5. 10.3 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Type (2021-2032)
  6. 10.4 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2032)
  7. 10.4.1 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2026)
  8. 10.4.2 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2027-2032)
  9. 10.5 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (2021-2032)
  2. 11.2 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2027-2032)
  5. 11.3 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2027-2032)
  9. 11.5 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country
  11. 11.6.1 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (2021-2032)
  2. 12.2 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country
  11. 12.6.1 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst